|Table of Contents|

Analysis of factors influencing bone metastasis in prostate cancer and construction of predictive model

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 22
Page:
4349-4354
Research Field:
Publishing date:

Info

Title:
Analysis of factors influencing bone metastasis in prostate cancer and construction of predictive model
Author(s):
ZHOU Wenkao1; CHEN Peijie2; HUANG Lingyan1; ZHAO Fangli1; TANG Huimin1; WANG Mingshan1
1.Xiang'An Hospital of Xiamen University,Fujian Xiamen 361000,China;2.Zhongshan Hospital of Xiamen University，Fujian Xiamen 361000,China.
Keywords:
PCBM; risk factors; predictive model; prognostic survival
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2024.22.022
Abstract:
Objective:To explore the risk factors influencing prostate cancer bone metastasis,establish predictive models related to hematological and pathological factors,and analyze the factors affecting PCBM survival.Methods:A total of 452 PC patients were included,divided into the PCBM group (n=169) and non PCBM group (n=283).Chi-square test,independent sample t-test,and Mann-Whitney U test were employed to analyze inter-group differences.Logistic regression was utilized to identify PCBM risk factors,upon which a clinical predictive model for PCBM was constructed.ROC and PR curves were used to validate the model's performance,and Kaplan-Meier curves were generated for PCBM-related survival analysis.Results:Comprehensive analysis through inter-group differences and Logistic regression revealed that T staging,N staging,PSA,ISUP,PNI,NLR,PLR,LMR,SII,HRR,HALP,and Serum P were the primary risk factors influencing PCBM（P＜0.05）.Based on these risk factors,a predictive model related to hematological and pathological factors was constructed,achieving accuracies of 0.972 and 0.932 in the training and testing sets,respectively.Survival curves demonstrated that T staging,N staging,PSA,and ISUP were the primary factors affecting PCBM survival.Conclusion:Risk factors for PCBM encompass pathological staging,PSA levels,and specific hematological indices.Our center established a related predictive model for predicting metastasis and survival in patients.

References:

［1］ SEKHOACHA M,RIET K,MOTLOUNG P,et al.Prostate cancer review:genetics,diagnosis,treatment options,and alternative approaches［J］.Molecules,2022,27(17):5730-5763.
［2］ 王安波,冯丽佳,倪萍萍,等.68Ga标记前列腺特异性膜抗原与18F标记氟化钠PET/CT对前列腺癌骨转移瘤的诊断效能［J］.中国医学科学院学报,2023,45(4):634-639. WANG AB,FENG LJ,NI PP,et al.Diagnostic efficacy of 68Ga-labeled prostate-specific membrane antigen and 18F-labeled sodium fluoride PET/CT in prostate cancer with bone metastasis［J］.Acta Academiae Medicinae Sinicae,2023,45(4):634-639.
［3］ MOHSENINIA N,ZAMANI-SIAHKALI N,HARSINI S,et al.Bone metastasis in prostate cancer:bone scan versus PET imaging［J］.Semin Nucl Med,2024,54(1):97-118.
［4］ GENG X,CHANG B,SHAN J.Role and correlation of exosomes and integrins in bone metastasis of prostate cancer［J］.Andrologia,2022,54(10):e14550-e14563.
［5］ KANG J,LA MANNA F,BONOLLO F,et al.Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer［J］.Cancer Lett,2022,530:156-169.
［6］ CHAOYING L,CHAO M,XIANGRUI Y,et al.Risk factors of bone metastasis in patients with newly diagnosed prostate cancer［J］.Eur Rev Med Pharmacol Sci,2022,26(2):391-398.
［7］ 陈桃芬,林雯丽,范华娜,等.血清转化生长因子、碱性磷酸酶、前列腺特异性抗原与转移性去势抵抗型前列腺癌的相关性分析［J］.重庆医科大学学报,2023,48(08):916-920. CHEN TF,LIN WL,FAN HN,et al.Correlation analysis of serum transforming growth factor,alkaline phosphatase,prostate-specific antigen and metastatic castration resistant prostate cancer［J］.Journal of Chongqing Medical University,2023,48(08):916-920.
［8］ VIETRI MT,D' ELIA G,CALIENDO G,et al.Hereditary prostate cancer:genes related,target therapy and prevention［J］.Int J Mol Sci,2021,22(7):3753-3770.
［9］ ZHOU W,ZHANG W,YAN S,et al.Novel therapeutic targets on the horizon:an analysis of clinical trials on therapies for bone metastasis in prostate cancer［J］.Cancers (Basel),2024,16(3):627-644.
［10］ HUANG R,WANG S,WANG N,et al.CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling［J］.Cell Death Dis,2020,11(4):234-254.
［11］ WANG L,XU M,KAO CY,et al.Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1［J］.J Clin Invest,2020,130(4):1782-1792.
［12］ LIN SR,MOKGAUTSI N,LIU YN.Ras and Wnt interaction contribute in prostate cancer bone metastasis［J］.Molecules,2020,25(10):2380-2397.
［13］ MATSUSHITA M,FUJITA K,NONOMURA N.Influence of diet and nutrition on prostate cancer［J］.Int J Mol Sci,2020,21(4):1447-1465.
［14］ ZAFFARONI M,VINCINI MG,CORRAO G,et al.Investigating nutritional and inflammatory status as predictive biomarkers in oligoreccurent prostate cancer-A RADIOSA trial preliminary analysis［J］.Nutrients,2023,15(21):4583-4597.
［15］ ZHANG JY,GE P,ZHANG PY,et al.Role of neutrophil to lymphocyte ratio or platelet to lymphocyte ratio in prediction of bone metastasis of prostate cancer［J］.Clin Lab,2019,65(5):1-11.
［16］ WANG Q,OU T,LI J,et al.Research on the association of plasma TGF-beta1 level and blood lymphocyte/monocyte ratio with pathological grade,clinical stage and prognosis of prostate cancer［J］.J BUON,2020,25(5):2418-2423.
［17］ WANG S,JI Y,CHEN Y,et al.The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in the localized prostate cancer and benign prostate hyperplasia:a retrospective clinical study［J］.Front Oncol,2021,11:812319-812326.
［18］ KOHAAR I,PETROVICS G,SRIVASTAVA S.A rich array of prostate cancer molecular biomarkers:opportunities and challenges［J］.Int J Mol Sci,2019,20(8):1813-1832.
［19］ ZHANG X.Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer［J］.Cancer Commun (Lond),2019,39(1):76-86.
［20］ CONNOR MJ,SHAH TT,HORAN G,et al.Cytoreductive treatment strategies for de novo metastatic prostate cancer［J］.Nat Rev Clin Oncol,2020,17(3):168-182.
［21］ 单雄威,吕世栋,陈丽萍,等.多中心研究PSA≤20 ng/mL前列腺癌临床特点及危险因素分析［J］.重庆医科大学学报,2023,48(08):931-934. SHAN XW,LYU SD,CHEN LP,et al.Clinical characteristics and risk factors for prostate cancer with PSA≤20 ng/mL:a multicenter study［J］.Journal of Chongqing Medical University,2023,48(08):931-934.
［22］ HABERAL HB,ARTYKOV M,HAZIR B,et al.Predictors of ISUP score upgrade in patients with low-risk prostate cancer［J］.Tumori,2021,107(3):254-260.

Memo

Memo:
-
Last Update: 1900-01-01